Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus.

Hanna Phan, Kyle Porter, Bruce Sill, Milap C. Nahata

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Little is known about U.S. outpatient prescribing trends for type 2 diabetes (T2DM) in adolescents and young adults. To determine (a) trends in the outpatient prescribing of pharmacological and nonpharmacological therapies and (b) factors influencing prescribing trends for adolescents and young adults with T2DM. A retrospective, cross-sectional analysis was conducted on office visits of adolescents (12-17 years) and young adults (18-39 years) with T2DM or impaired glucose tolerance (IGT), using the National Ambulatory Medical Care Survey (NAMCS) from 1996-2005. Logistic regression was used to test for prescribing trends over time. There were an estimated 1.6 million (93.7% T2DM; 4.4% T2DM + IGT; 1.9% IGT) and 22.2 million (88.1% T2DM; 11.9% IGT) office visits for adolescents (0.4% of all adolescent visits) and young adults (1.2% of all young adult visits) associated with T2DM based on ICD-9-CM codes, respectively. In young adults, diabetes drug mentions increased significantly from 39% of visits with T2DM to 61% in 2004-2005 (P = 0.04). Oral diabetes medication mentions increased from 20% to 49% (P = 0.001). However, reports of nonpharmacological therapy decreased from 53% in 1996-1997 to 37% in 2004-2005 (P = 0.14). The prescribing of pharmacological treatment for T2DM increased with emphasis on oral agents, while reports of nonpharmacological therapy for T2DM decreased over the 9-year study period with increased use of oral medications in both adolescents and young adults. Health care providers should consistently consider both treatment approaches when prescribing patient care as recommended by treatment guidelines.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalJournal of managed care pharmacy : JMCP.
Volume18
Issue number8
StatePublished - Oct 2012

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Young Adult
Outpatients
Glucose Intolerance
Glucose
Health care
Office Visits
Therapeutics
Logistics
Pharmacology
Health Care Surveys
International Classification of Diseases
Health Personnel
Pharmaceutical Preparations
Patient Care
Cross-Sectional Studies
Logistic Models
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus. / Phan, Hanna; Porter, Kyle; Sill, Bruce; Nahata, Milap C.

In: Journal of managed care pharmacy : JMCP., Vol. 18, No. 8, 10.2012, p. 607-614.

Research output: Contribution to journalArticle

@article{c40ed4bcdb0c430caaed23499f5d4c96,
title = "Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus.",
abstract = "Little is known about U.S. outpatient prescribing trends for type 2 diabetes (T2DM) in adolescents and young adults. To determine (a) trends in the outpatient prescribing of pharmacological and nonpharmacological therapies and (b) factors influencing prescribing trends for adolescents and young adults with T2DM. A retrospective, cross-sectional analysis was conducted on office visits of adolescents (12-17 years) and young adults (18-39 years) with T2DM or impaired glucose tolerance (IGT), using the National Ambulatory Medical Care Survey (NAMCS) from 1996-2005. Logistic regression was used to test for prescribing trends over time. There were an estimated 1.6 million (93.7{\%} T2DM; 4.4{\%} T2DM + IGT; 1.9{\%} IGT) and 22.2 million (88.1{\%} T2DM; 11.9{\%} IGT) office visits for adolescents (0.4{\%} of all adolescent visits) and young adults (1.2{\%} of all young adult visits) associated with T2DM based on ICD-9-CM codes, respectively. In young adults, diabetes drug mentions increased significantly from 39{\%} of visits with T2DM to 61{\%} in 2004-2005 (P = 0.04). Oral diabetes medication mentions increased from 20{\%} to 49{\%} (P = 0.001). However, reports of nonpharmacological therapy decreased from 53{\%} in 1996-1997 to 37{\%} in 2004-2005 (P = 0.14). The prescribing of pharmacological treatment for T2DM increased with emphasis on oral agents, while reports of nonpharmacological therapy for T2DM decreased over the 9-year study period with increased use of oral medications in both adolescents and young adults. Health care providers should consistently consider both treatment approaches when prescribing patient care as recommended by treatment guidelines.",
author = "Hanna Phan and Kyle Porter and Bruce Sill and Nahata, {Milap C.}",
year = "2012",
month = "10",
language = "English (US)",
volume = "18",
pages = "607--614",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "8",

}

TY - JOUR

T1 - Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus.

AU - Phan, Hanna

AU - Porter, Kyle

AU - Sill, Bruce

AU - Nahata, Milap C.

PY - 2012/10

Y1 - 2012/10

N2 - Little is known about U.S. outpatient prescribing trends for type 2 diabetes (T2DM) in adolescents and young adults. To determine (a) trends in the outpatient prescribing of pharmacological and nonpharmacological therapies and (b) factors influencing prescribing trends for adolescents and young adults with T2DM. A retrospective, cross-sectional analysis was conducted on office visits of adolescents (12-17 years) and young adults (18-39 years) with T2DM or impaired glucose tolerance (IGT), using the National Ambulatory Medical Care Survey (NAMCS) from 1996-2005. Logistic regression was used to test for prescribing trends over time. There were an estimated 1.6 million (93.7% T2DM; 4.4% T2DM + IGT; 1.9% IGT) and 22.2 million (88.1% T2DM; 11.9% IGT) office visits for adolescents (0.4% of all adolescent visits) and young adults (1.2% of all young adult visits) associated with T2DM based on ICD-9-CM codes, respectively. In young adults, diabetes drug mentions increased significantly from 39% of visits with T2DM to 61% in 2004-2005 (P = 0.04). Oral diabetes medication mentions increased from 20% to 49% (P = 0.001). However, reports of nonpharmacological therapy decreased from 53% in 1996-1997 to 37% in 2004-2005 (P = 0.14). The prescribing of pharmacological treatment for T2DM increased with emphasis on oral agents, while reports of nonpharmacological therapy for T2DM decreased over the 9-year study period with increased use of oral medications in both adolescents and young adults. Health care providers should consistently consider both treatment approaches when prescribing patient care as recommended by treatment guidelines.

AB - Little is known about U.S. outpatient prescribing trends for type 2 diabetes (T2DM) in adolescents and young adults. To determine (a) trends in the outpatient prescribing of pharmacological and nonpharmacological therapies and (b) factors influencing prescribing trends for adolescents and young adults with T2DM. A retrospective, cross-sectional analysis was conducted on office visits of adolescents (12-17 years) and young adults (18-39 years) with T2DM or impaired glucose tolerance (IGT), using the National Ambulatory Medical Care Survey (NAMCS) from 1996-2005. Logistic regression was used to test for prescribing trends over time. There were an estimated 1.6 million (93.7% T2DM; 4.4% T2DM + IGT; 1.9% IGT) and 22.2 million (88.1% T2DM; 11.9% IGT) office visits for adolescents (0.4% of all adolescent visits) and young adults (1.2% of all young adult visits) associated with T2DM based on ICD-9-CM codes, respectively. In young adults, diabetes drug mentions increased significantly from 39% of visits with T2DM to 61% in 2004-2005 (P = 0.04). Oral diabetes medication mentions increased from 20% to 49% (P = 0.001). However, reports of nonpharmacological therapy decreased from 53% in 1996-1997 to 37% in 2004-2005 (P = 0.14). The prescribing of pharmacological treatment for T2DM increased with emphasis on oral agents, while reports of nonpharmacological therapy for T2DM decreased over the 9-year study period with increased use of oral medications in both adolescents and young adults. Health care providers should consistently consider both treatment approaches when prescribing patient care as recommended by treatment guidelines.

UR - http://www.scopus.com/inward/record.url?scp=84874575285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874575285&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 607

EP - 614

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 8

ER -